Are you interested in contributing to research on COVID-19 vaccines? We are conducting a clinical study evaluating an investigational vaccine that may help protect against the Omicron JN.1 subvariant of COVID-19.
HomeCategory
50-64 years of age
The BeyondCOVE Trial is doing further research on 2 approved COVID-19 vaccines to learn more about how well the vaccines can protect against COVID-19 illness caused by the SARS-CoV-2 virus and its multiple variants.
The trial will last about 6 months and has 2 trial visits and 2 phone call check-ins. All participants will receive 1 injection.
To join the trial, you must:
- At the time of signing the informed consent form (ICF), be 50 to 64 years of age
- Be in general good health
- Not have tested positive for COVID-19 or received a COVID-19 vaccine within the past 3 months
- Not have received a flu vaccine within 14 days before or after the trial injection, or any other vaccines 28 days before or after the trial injection
- Be capable of complying with all trial requirements
There are additional requirements, which the trial team can explain to you.
To learn more about this trial, please contact the clinical trial site listed here:
786-772-0510
Diseases do not discriminate — and neither should clinical trials. Moderna is committed to researching safe and effective mRNA-based vaccines and therapies to bring better health and living to people of all ages, sexes, and backgrounds.
The Duo P201 Trial Part 2 will evaluate the safety and immune response of 2 batches of an investigational combination vaccine aimed at preventing both seasonal flu and COVID-19 infections in adults 50 to 64 years of age.
The Duo P201 Trial will evaluate the safety and immune response of 4 batches of an investigational combination vaccine aimed at preventing both seasonal flu and COVID-19 infections in adults 50 to 64 years of age.
Streptococcus pneumoniae is a common type of bacteria (germ) that can cause a wide variety of diseases, ranging from mild sinus and ear infections to more serious infections of the lungs, lining of the brain, or blood that require hospitalization and can be life-threatening. While anyone can get pneumococcal disease, adults over 50 have a higher risk of experiencing severe illness and are 8 times more likely to be hospitalized with pneumococcal pneumonia than younger adults.
According to the Centers for Disease Control and Prevention (CDC), getting vaccinated is the best way to help protect against pneumococcal disease. The CDC recommends that adults 65 years of age and older receive a pneumococcal vaccine as part of their routine vaccinations.
The vaccines available today protect against many strains of pneumococcal bacteria, but not all of them. That’s why we thought you may be interested in learning about Pfizer’s pneumococcal vaccine clinical trial designed to broaden protection against more bacterial strains.
We’re currently enrolling people who are:
- 50 to 64 years of age and have not previously received a pneumococcal vaccine.
- 65 years of age or older and have either not received a pneumococcal vaccine or have received the PNEUMOVAX® 23 vaccine more than 5 years ago.
Taking part in this clinical trial could potentially improve vaccine protection not only for you, but also others in the future.
Interested in joining this study? Here’s what you can expect if you take part:
- The study will last about one year, and you will attend at least 4 study visits.
- You will be randomly assigned to receive one dose of either the study vaccine or a licensed pneumococcal vaccine made by Pfizer (Prevnar 20®). You have an equal chance of being assigned to either vaccine group. There is no placebo (a shot with no active ingredient) in this study.
- Your safety is always our top priority. Our medical team will closely monitor your health while you are in the study. You can also leave this clinical trial at any time and for any reason.
- There is no cost to participate, and health insurance is not required. You will also be paid for completing study-related activities.
Please contact our team for more information. We’ll review the study’s requirements with you to help you decide if this clinical trial is a good fit for you.
Indago delivers community-based services for Miami and neighboring areas, driving advances in investigational research for new and improved drugs.
Working Hours
Monday-Friday 8:00 AM – 5:00 PM
Saturday (open if necessary)
Sunday (open if necessary)